Fwd: Severity and Long-Term Mortality of COVID-19, Influenza, and Respiratory Syncytial Virus

Enviado desde mi iPhone

Inicio del mensaje reenviado:



https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2829342?guestAccessKey=81920507-4661-4a42-93a8-1ecf2e86a119&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jamainternalmedicine&utm_content=olf&utm_term=012725&adv=000004320864

Conclusions and Relevance  This cohort study showed that, during the 2022 to 2023 season, infection with SARS-CoV-2 was associated with more severe disease outcomes than influenza or RSV, whereas differences were less pronounced during the 2023 to 2024 season. During both seasons, RSV remained a milder illness, whereas COVID-19 was associated with higher long-term mortality. Vaccination attenuated differences in disease severity and long-term mortality.